Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00207142
Status:
COMPLETED
Last Update Posted:
2010-01-12
First Post:
2005-09-16
Brief Title:
Induction-Maintenance With Atazanavir in HIV Naïve Patients The INDUMA Study
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase IV Open-Label Randomized Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase With Unboosted vs Boosted Reyataz After an Induction Phase With Reyataz and Ritonavir in Treatment Naive HIV Patients the INDUMA Study
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
INDUMA
Brief Summary:
The purpose of this study is to compare the proportion of subjects with HIV-1 RNA viral load 50 cmL through Week 48 of the Maintenance Phase among HIV-infected subjects with an initial undetectable viral load following an Induction Phase with an ATVRTV containing HAART regimen when switched to ATV versus remaining on ATVRTV whilst continuing their previous NRTI backbone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None